UroGen Pharma Ltd (URGN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $43.25 (-1.59%), Market cap $1.28B, 52-week low–high $3.93 ~ $29.42.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that
Financial statements, price targets, institutional (13F) holdings and related news for UroGen Pharma Ltd are updated in real time on BlackAll Trade.
UroGen Pharma Ltd trades at $43.25 (-1.59%). Real-time quotes and charts are available on BlackAll Trade.
UroGen Pharma Ltd has a market cap of about $1.28B.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompa